{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T20:57:04Z","timestamp":1760821024409,"version":"3.37.3"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T00:00:00Z","timestamp":1539907200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-4885-5","type":"journal-article","created":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T06:42:46Z","timestamp":1539931366000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Low-dose trofosfamide plus rituximab is an effective and safe treatment for diffuse large B-cell lymphoma of the elderly: a single center experience"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3466-5866","authenticated-orcid":false,"given":"Roland Christian","family":"Schelker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Herr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albrecht","family":"Reichle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Vogelhuber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,19]]},"reference":[{"key":"4885_CR1","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","volume":"107","author":"LM Morton","year":"2006","unstructured":"Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107:265\u201376.","journal-title":"Blood"},{"issue":"5","key":"4885_CR2","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1093\/oxfordjournals.annonc.a058211","volume":"3","author":"F d\u2019Amore","year":"1992","unstructured":"d\u2019Amore F, Brincker H, Christensen BE, Thorling K, Pedersen M, Nielsen JL, et al. Non-Hodgkin\u2019s lymphoma in the elderly. A study of 602 patients aged 70 or older from a Danish population-based registry. The Danish LYEO-Study Group. Ann Oncol. 1992;3(5):379\u201386.","journal-title":"Ann Oncol"},{"key":"4885_CR3","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1002\/1097-0142(19880515)61:10<2057::AID-CNCR2820611021>3.0.CO;2-X","volume":"61","author":"B Hoerni","year":"1988","unstructured":"Hoerni B, Sotto JJ, Eghbali H, Sotto MF, Noerni-Simon G, Pegouri\u00e9 B. Non-Hodgkin\u2019s malignant lymphomas in patients older than 80: 70 cases. Cancer. 1988;61:2057\u20139.","journal-title":"Cancer"},{"key":"4885_CR4","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1093\/annonc\/mdl034","volume":"17","author":"O Bairey","year":"2006","unstructured":"Bairey O, Benjamini O, Blickstein D, Elis A, Ruchlemer R. Non-Hodgkin\u2019s lymphoma in patients 80 years of age or older. Ann Oncol. 2006;17:928\u201334.","journal-title":"Ann Oncol"},{"key":"4885_CR5","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1093\/annonc\/mdm563","volume":"19","author":"C Thieblemont","year":"2008","unstructured":"Thieblemont C, Grossoeuvre A, Houot R, Broussais-Guillaumont F, Salles G, Traull\u00e9 C, et al. Non-Hodgkin\u2019s lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. Ann Oncol. 2008;19:774\u20139.","journal-title":"Ann Oncol"},{"key":"4885_CR6","first-page":"1281","volume":"90","author":"A Italiano","year":"2005","unstructured":"Italiano A, Jardin F, Peyrade F, Saudes L, Tilly H, Thyss A. Adapted CHOP plus rituximab in non-Hodgkin\u2019s lymphoma in patients over 80 years old. Haematologica. 2005;90:1281\u20133.","journal-title":"Haematologica"},{"key":"4885_CR7","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1182\/blood-2011-10-388470","volume":"119","author":"W Klapper","year":"2012","unstructured":"Klapper W, Kreuz M, Kohler CW, Burkhardt B, Szczepanowski M, Salaverria I, et al. Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma. Blood. 2012;119:1882\u20137.","journal-title":"Blood"},{"key":"4885_CR8","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/j.1532-5415.1984.tb02020.x","volume":"32","author":"JO Armitage","year":"1984","unstructured":"Armitage JO, Potter JF. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: increased complications with advancing age. J Am Geriatr Scc. 1984;32:269\u201373.","journal-title":"J Am Geriatr Scc"},{"key":"4885_CR9","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1200\/JCO.1997.15.8.2945","volume":"15","author":"Y Bastion","year":"1997","unstructured":"Bastion Y, Blay JY, Divine M, Brice P, Bordessoule D, Sebban C, et al. Elderly patients with aggressive non-Hodgkin\u2019s lymphoma: disease presentation, response to treatment, and survival \u2013 a group d\u2019\u00e9tude des Lymphomes de l\u2019Adulte study on 453 patients older than 69 years. J Clin Oncol. 1997;15:2945\u201353.","journal-title":"J Clin Oncol"},{"key":"4885_CR10","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/annonc\/mdg067","volume":"14","author":"EM Bessell","year":"2003","unstructured":"Bessell EM, Burton A, Haynes AP, Glaholm J, Child JA, Cullen MH, et al. A randomized multicenter trial of modified CHOP versus MCOP in patients aged 65 years and over with aggressive non-Hodgkin\u2019s lymphoma. Ann Oncol. 2003;14:258\u201367.","journal-title":"Ann Oncol"},{"key":"4885_CR11","doi-asserted-by":"publisher","first-page":"3840","DOI":"10.1182\/blood-2002-10-3238","volume":"101","author":"E Osby","year":"2003","unstructured":"Osby E, Hagberg H, Kvaloy S, Teerenhovi L, Anderson H, Cavallin-Stahl E, et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic lymphoma group randomized trial. Blood. 2003;101:3840\u20138.","journal-title":"Blood"},{"key":"4885_CR12","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235\u201342.","journal-title":"N Engl J Med"},{"issue":"18","key":"4885_CR13","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","volume":"23","author":"P Feugier","year":"2005","unstructured":"Feugier P, Van Hoof A, Sebban C, Dolal-Celigny P, Bouabdallah R, Ferm\u00e9 C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol. 2005;23(18):4117\u201326.","journal-title":"J Clin Oncol"},{"key":"4885_CR14","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","volume":"116","author":"B Coiffier","year":"2010","unstructured":"Coiffier B, Thieblemont C, van den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte. Blood. 2010;116:2040\u20135.","journal-title":"Blood"},{"key":"4885_CR15","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","volume":"9","author":"M Pfreundschuh","year":"2008","unstructured":"Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a 17onrandomi controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105\u201316.","journal-title":"Lancet Oncol"},{"key":"4885_CR16","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","volume":"24","author":"TM Habermann","year":"2006","unstructured":"Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:3121\u20137.","journal-title":"J Clin Oncol"},{"key":"4885_CR17","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1080\/10428190802043853","volume":"49","author":"G Visani","year":"2008","unstructured":"Visani G, Ferrara F, Alesiani F, Ronconi S, Catarini M, D\u2019adamo F, et al. R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: a pilot study. Leuk Lymphoma. 2008;49:1081\u20136.","journal-title":"Leuk Lymphoma"},{"key":"4885_CR18","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/j.1365-2141.2011.08786.x","volume":"154","author":"G Corazzelli","year":"2011","unstructured":"Corazzelli G, Frigeri F, Arcamone M, Lucania A, Rosariavilla M, Morelli E, et al. Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high \u2018life threat\u2019 impact cardiopathy. Brit J Haematol. 2011;154:579\u201389.","journal-title":"Brit J Haematol"},{"issue":"1","key":"4885_CR19","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/hon.2386","volume":"36","author":"Giuseppina Ricciuti","year":"2017","unstructured":"Ricciuti G, Finolezzi e LS, Ranucci E, Federico M, Di Nicola M, et al. Combination of rituximab and nonpegylated liposomal doxorubicin (R-NPLD) as front-line therapy for aggressive non-Hodgkin lymphoma (NHL) in patients 80 years of age or older: a single-center retrospective study. Hematol Oncol. 2017. \n                    https:\/\/doi.org\/10.1002\/hon.2386\n                    \n                  .","journal-title":"Hematological Oncology"},{"issue":"12","key":"4885_CR20","first-page":"22497","volume":"8","author":"D Zhou","year":"2015","unstructured":"Zhou D, Li L, Bao C, Zhu J, Zhu L, Yang X, et al. Replacement of conventional doxorubicin by pegylated liposomal doxorubicin in standard RCHOP chemotherapy for elderly diffuse large B-cell lymphoma: a retrospective study in China. Int J Clin Exp Med. 2015;8(12):22497\u2013502.","journal-title":"Int J Clin Exp Med"},{"key":"4885_CR21","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","volume":"12","author":"F Peyrade","year":"2011","unstructured":"Peyrade F, Jardin F, Thieblemont C, Thyss A, Emile JF, Castaigne S, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a 18onrandomiz, single-arm, phase 2 trial. Lancet Oncol. 2011;12:460\u20138.","journal-title":"Lancet Oncol"},{"key":"4885_CR22","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1002\/cncr.25582","volume":"117","author":"A Musolino","year":"2011","unstructured":"Musolino A, Boggiani D, Panebianco M, Fontana E, Zanoni D, Bozzetti C, et al. Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma. Cancer. 2011;117:964\u201373.","journal-title":"Cancer"},{"key":"4885_CR23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3816\/CLML.2010.n.004","volume":"10","author":"JD Hainsworth","year":"2010","unstructured":"Hainsworth JD, Flinn IW, Spigel DR, Clark BL, Griner PL, Vazquez ER, et al. Brief-duration rituximab\/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon oncology research consortium. Clin Lymph Myel Leuk. 2010;10:44\u201350.","journal-title":"Clin Lymph Myel Leuk"},{"key":"4885_CR24","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1200\/JCO.2013.49.7586","volume":"32","author":"FA Fields","year":"2014","unstructured":"Fields FA, Townsend W, Webb A, Counsell N, Pocock C, Smith P, et al. De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute project. J Clin Oncol. 2014;32:282\u20137.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4885_CR25","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1016\/S2352-3026(16)30171-5","volume":"4","author":"F Peyrade","year":"2017","unstructured":"Peyrade F, Bologna S, Delwail V, Emile JF, Pascal L, Ferm\u00e9 C, et al. Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicenter, single-arm, phase 2 trial from the LYSA group. Lancet Haematol. 2017;4(1):e46\u201355.","journal-title":"Lancet Haematol"},{"issue":"20","key":"4885_CR26","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.1002\/cncr.30173","volume":"122","author":"D Chihara","year":"2016","unstructured":"Chihara D, Westin JR, Oki Y, Ahmed MA, Do B, Fayad LE, et al. Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. Cancer. 2016;122(20):3145\u201351.","journal-title":"Cancer"},{"issue":"7","key":"4885_CR27","doi-asserted-by":"publisher","first-page":"819","DOI":"10.3109\/02841869109091828","volume":"30","author":"E Wist","year":"1991","unstructured":"Wist E, Risberg T. Trofosfamide in non-Hodgkin\u2019s lymphoma. A phase II study. Acta Oncol. 1991;30(7):819\u201321.","journal-title":"Acta Oncol"},{"issue":"2","key":"4885_CR28","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1159\/000227672","volume":"54","author":"E Salminen","year":"1997","unstructured":"Salminen E, Nikkanen V, Lindholm L. Palliative chemotherapy in non-Hodgkin\u2019s lymphoma. Oncology. 1997;54(2):108\u201311.","journal-title":"Oncology"},{"issue":"3","key":"4885_CR29","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/S0959-8049(97)89029-6","volume":"33","author":"MD Helsing","year":"1997","unstructured":"Helsing MD. Trofosfamide as a salvage treatment with low toxicity in malignant lymphoma. A phase II study. Eur J Cancer. 1997;33(3):500\u20132.","journal-title":"Eur J Cancer"},{"key":"4885_CR30","first-page":"134","volume":"22","author":"GJ Wiedemann","year":"1999","unstructured":"Wiedemann GJ, Zschaber R, Hegewisch-Becker S, Reichardt P, Weber K, Uthgenannt D, et al. Two oral trofosfamide schedules in elderly patients with refractory non-Hodgkin\u2019s lymphoma. Onkologie. 1999;22:134\u20138.","journal-title":"Onkologie"},{"key":"4885_CR31","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1080\/1042819021000040053","volume":"43","author":"PO Andersson","year":"2002","unstructured":"Andersson PO, Braide I, Nilsson-Ehle H. Trofosfamide as a salvage therapy for anaplastic large cell lymphoma relapsing after high dose chemotherapy. Leuk Lymphoma. 2002;43:2351\u20133.","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"4885_CR32","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s12307-015-0170-1","volume":"8","author":"C Hart","year":"2015","unstructured":"Hart C, Vogelhuber M, Wolff D, Klobuch S, Ghibelli L, Foell J, et al. Anakoinosis: communicative reprogramming of tumor systems \u2013 for rescuing from chemorefractory neoplasia. Cancer Microenviron. 2015;8(2):75\u201392.","journal-title":"Cancer Microenviron"},{"issue":"2","key":"4885_CR33","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1200\/JCO.2012.44.2053","volume":"31","author":"B Aigner","year":"2013","unstructured":"Aigner B, Richtig E, Becker JC, Lingitz H, Marterer R, Niederkorn A, et al. Partial response of metastatic mucosal melanoma after palliative chemotherapy with trofosfamide: a case report. J Clin Oncol. 2013;31(2):e31\u20132.","journal-title":"J Clin Oncol"},{"key":"4885_CR34","doi-asserted-by":"publisher","first-page":"376","DOI":"10.5414\/CPP40376","volume":"40","author":"A Brinker","year":"2002","unstructured":"Brinker A, Kisro J, Letsch C, Br\u00fcggemann SK, Wagner T, et al. New insights into the pharmacokinetics of trofosfamide. Int J Clin Pharmacol Ther. 2002;40:376\u201381.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"4885_CR35","first-page":"2075","volume":"30","author":"H Lindemann","year":"1980","unstructured":"Lindemann H, Harbers E. Interaction of three alkylating drugs, cyclophosphamide, ifosfamide and trofosfamide with DNA and DNA-constituents in vitro. Arzneimittelforschung. 1980;30:2075\u201380.","journal-title":"Arzneimittelforschung"},{"issue":"Suppl 4","key":"4885_CR36","first-page":"24","volume":"25","author":"T Klink","year":"2002","unstructured":"Klink T, Marxsen JH, Wagner T. Trofosfamide equally inhibits endothelial and tumor cell growth. Onkologie. 2002;25(Suppl 4):24 (A85).","journal-title":"Onkologie"},{"key":"4885_CR37","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s002800050623","volume":"40","author":"G Hempel","year":"1997","unstructured":"Hempel G, Krumpelmann S, May-Manske A, Hohenl\u00f6chter B, Blaschke G, J\u00fcrgens H, et al. Pharmacokinetics of trofosfamide and its dechloroethyl-metabolites. Cancer Chemother Pharmacol. 1997;40:45\u201350.","journal-title":"Cancer Chemother Pharmacol"},{"key":"4885_CR38","first-page":"572","volume":"27","author":"D Latz","year":"2004","unstructured":"Latz D, Nassar N, Frank R. Trofosfamide in the palliative treatment of cancer: a review of the literature. Onkologie. 2004;27:572\u20136.","journal-title":"Onkologie"},{"issue":"20","key":"4885_CR39","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375\u201390.","journal-title":"Blood"},{"key":"4885_CR40","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"A predictive model for aggressive non-Hodgkin's lymphoma","year":"1993","unstructured":"A predictive model for aggressive non-Hodgkin's lymphoma. The international non-Hodgkin's lymphoma prognostic factors project. N Engl J Med. 1993;329:987\u201394.","journal-title":"N Engl J Med"},{"key":"4885_CR41","first-page":"1860","volume":"31","author":"PP Carbone","year":"1971","unstructured":"Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M, et al. Report of the committee on Hodgkin\u2019s disease staging classification. Cancer Res. 1971;31:1860\u20131.","journal-title":"Cancer Res"},{"key":"4885_CR42","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579\u201386.","journal-title":"J Clin Oncol"},{"key":"4885_CR43","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 1982;5:649\u201355.","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"4885_CR44","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1182\/blood.V87.2.495.bloodjournal872495","volume":"87","author":"D Hoelzer","year":"1996","unstructured":"Hoelzer D, Ludwig WD, Thiel E, Gassmann W, L\u00f6ffler H, Fonatsch C, et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood. 1996;87(2):495\u2013508.","journal-title":"Blood"},{"issue":"4","key":"4885_CR45","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1080\/17474086.2017.1305264","volume":"10","author":"A Chiappella","year":"2017","unstructured":"Chiappella A, Castellino A, Nicolosi M, Santambrogio E, Vitolo U. Diffuse large B-cell lymphoma in the elderly: standard treatment and new perspectives. Expert Rev Hematol. 2017;10(4):289\u201397.","journal-title":"Expert Rev Hematol"},{"issue":"10","key":"4885_CR46","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s00277-016-2768-x","volume":"95","author":"K Laribi","year":"2016","unstructured":"Laribi K, Denizon N, Bolle D. R-CVP regimen is active in frail elderly patients aged 80 or over with diffuse large B cell lymphoma. Ann Hematol. 2016;95(10):1705\u201314.","journal-title":"Ann Hematol"},{"issue":"2","key":"4885_CR47","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/bjh.14232","volume":"175","author":"SI Park","year":"2016","unstructured":"Park SI, Grover NS, Olajide O, Asch AS, Wall JG, Richards KL, et al. A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma. Br J Haematol. 2016;175(2):281\u20139.","journal-title":"Br J Haematol"},{"key":"4885_CR48","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1093\/annonc\/mdq671","volume":"22","author":"E Weidmann","year":"2011","unstructured":"Weidmann E, Neumann A, Fauth F, Atmaca A, Al-Batran SE, Pauligk C, et al. Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. Ann Oncol. 2011;22:1839\u201344.","journal-title":"Ann Oncol"},{"key":"4885_CR49","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.3109\/10428194.2012.682311","volume":"53","author":"E Walter","year":"2012","unstructured":"Walter E, Schmitt T, Dietrich S, Ho A, Witzens-Harig M. Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy. Leuk Lymphoma. 2012;53:2290\u20132.","journal-title":"Leuk Lymphoma"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4885-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-4885-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4885-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T19:15:05Z","timestamp":1571426105000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-4885-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,19]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4885"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-4885-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"type":"electronic","value":"1471-2407"}],"subject":[],"published":{"date-parts":[[2018,10,19]]},"assertion":[{"value":"18 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The retrospective patient analysis is in accordance with the current version of the Helsinki Declaration and is approved by the local Ethics Committee of Human Experimentation, University Regensburg (reference number: 17\u2013667-104).Informed consent was obtained written from each patient that drugs, approved for lymphoma therapy should be used, which have not been tested in combination, yet.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"1000"}}